H.C. Wainwright raised the firm’s price target on AxoGen (AXGN) to $50 from $39 and keeps a Buy rating on the shares following the Q1 sales beat. AxoGen is an “execution story focused on achieving profitable and sustainable growth,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN: